{
    "Trade/Device Name(s)": [
        "OVA1 Next Generation"
    ],
    "Submitter Information": "Vermillion, Inc.",
    "510(k) Number": "K150588",
    "Predicate Device Reference 510(k) Number(s)": [
        "K081754"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "ONX"
    ],
    "Summary Letter Date": "February 22, 2016",
    "Summary Letter Received Date": "March 1, 2016",
    "Submission Date": "March 6, 2015",
    "Regulation Number(s)": [
        "21 CFR 866.6050"
    ],
    "Regulation Name(s)": [
        "Ovarian adnexal mass assessment score test system"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Apolipoprotein A-1",
        "CA 125 II",
        "Follicle Stimulating Hormone (FSH)",
        "Human epididymis protein 4 (HE4)",
        "Transferrin (TRF)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        "Roche cobas 6000 system",
        "Roche cobas c501",
        "Roche cobas e601"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoassay",
        "Automated clinical chemistry analysis",
        "Software risk score algorithm"
    ],
    "Methodologies": [
        "Risk score calculation from biomarker immunoassays"
    ],
    "Submission Type(s)": [
        "Test",
        "Software",
        "Assay",
        "Reagent",
        "Analyzer",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Vermillion OVA1 Next Generation test combining five immunoassays with risk score algorithm for ovarian adnexal mass malignancy assessment",
    "Indications for Use Summary": "Aid for assessing malignancy risk in women over 18 with ovarian adnexal mass planned for surgery and not yet referred to an oncologist, used with independent clinical and imaging evaluation; not for screening or stand-alone diagnosis",
    "fda_folder": "Obstetrics"
}